A detailed history of Cwm, LLC transactions in Galapagos Nv stock. As of the latest transaction made, Cwm, LLC holds 8 shares of GLPG stock, worth $230. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8
Previous 8 -0.0%
Holding current value
$230
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

Sep 15, 2021

SELL
$76.15 - $111.94 $2,665 - $3,917
-35 Reduced 81.4%
8 $1,000
Q1 2021

Apr 27, 2021

BUY
$76.15 - $111.94 $2,665 - $3,917
35 Added 437.5%
43 $3,000
Q4 2020

Sep 15, 2021

BUY
$96.85 - $148.25 $774 - $1,186
8 New
8 $1,000
Q4 2020

Jan 27, 2021

SELL
$96.85 - $148.25 $774 - $1,186
-8 Closed
0 $0
Q3 2020

Sep 15, 2021

BUY
$122.47 - $213.56 $979 - $1,708
8 New
8 $1,000
Q3 2020

Oct 19, 2020

SELL
$122.47 - $213.56 $979 - $1,708
-8 Closed
0 $0
Q2 2020

Sep 15, 2021

BUY
$185.52 - $231.25 $1,484 - $1,850
8 New
8 $1,000
Q2 2020

Jul 22, 2020

SELL
$185.52 - $231.25 $1,484 - $1,850
-8 Closed
0 $0
Q1 2020

Sep 15, 2021

BUY
$143.0 - $274.03 $1,144 - $2,192
8 New
8 $1,000
Q1 2020

Apr 28, 2020

SELL
$143.0 - $274.03 $1,144 - $2,192
-8 Closed
0 $0
Q4 2019

Sep 14, 2021

BUY
$146.12 - $215.82 $1,168 - $1,726
8 New
8 $1,000
Q4 2019

Jan 27, 2020

SELL
$146.12 - $215.82 $1,168 - $1,726
-8 Closed
0 $0
Q3 2019

Sep 14, 2021

BUY
$130.44 - $187.64 $1,043 - $1,501
8 New
8 $1,000
Q3 2019

Oct 22, 2019

SELL
$130.44 - $187.64 $1,043 - $1,501
-8 Closed
0 $0
Q2 2019

Sep 14, 2021

BUY
$111.45 - $128.93 $891 - $1,031
8 New
8 $1,000
Q2 2019

Jul 31, 2019

SELL
$111.45 - $128.93 $891 - $1,031
-8 Closed
0 $0
Q1 2019

Sep 02, 2021

BUY
$89.61 - $117.78 $716 - $942
8 New
8 $0

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.9B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.